A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia
Cancer · 15.05.2026 · 132 (10)
DOI: 10.1002/cncr.70432 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 12.05.2026. Verfasst von Xiao-Hua Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing Municipality, Joint Project of Chongqing Health Commission and Science and Technology Bureau.
Abstract (Originalsprache)
Background
Translation inhibitors have been shown to accelerate acute myeloid leukemia (AML) cell apoptosis and regulate Akt activity and the Bcl‐2 family, suggesting their potential benefit when combined with venetoclax and cytarabine in de novo AML patients.
Methods
The authors conducted a multicenter, open‐label, single‐arm study to assess the efficacy and safety of a venetoclax–cytarabine‐based induction regimen incorporating a clinically available translation inhibitor in adult patients newly diagnosed with AML in China.
Results
A total of 52 cases (median age, 48.5 years; range, 18–60) were treated, with poor risk in 27% (14 of 52) of patients. The overall response rate was 90% (95% CI, 79–97) after one cycle of the regimen with 46 patients in composite complete remission. With a median follow‐up of 816 days (interquartile range, 418–1143), the estimated 1‐year overall survival (OS) and event‐free survival (EFS) were both 81% (95% CI, 71–92). After induction chemotherapy, patients experienced decreases in CD4 + naive, CD8 + naive, Th2, and CD19 + cells, along with increases in CD4 + TEM, Th1, natural killer cells, and a higher Th1/Th2 ratio in both peripheral blood and bone marrow (BM), whereas BM‐specific changes included a decrease in CD8 + naive cells and lower IL‐10 levels post‐treatment.
Conclusion
This venetoclax–cytarabine regimen incorporating a translation inhibitor demonstrated efficacy and was well‐tolerated in young adult patients with de novo AML, achieving high complete remission rates and encouraging OS and EFS. The induced immune‐cell and cytokine shifts provide deeper insights into integrating translational inhibition with BCL2‐targeted therapies and warrant further investigation in randomized controlled trials. This trial was registered at ChiCTR.org.cn as ChiCTR2100048208.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Hematology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
- The Center for Clinical Molecular Medical Detection, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xiao-Hua Luo
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing Municipality
- Joint Project of Chongqing Health Commission and Science and Technology Bureau
- Basic Oncology Research Program from the Bethune Charitable Foundation
Zitieren
APA
Luo, X. H., Tang, N. N., Wang, L., Zhu, Y., Liu, L., Xu, S. N., Yang, L., Pei, C. X., Zhan, Q., Wang, X., & Chen, J. B. (2026). A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. Cancer, 132(10). https://doi.org/10.1002/cncr.70432
Vancouver
Luo XH, Tang NN, Wang L, Zhu Y, Liu L, Xu SN, et al. A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia. Cancer. 2026;132(10). doi:10.1002/cncr.70432
BibTeX
@article{Luo2026,
author = {Luo, Xiao-Hua and Tang, Na-Na and Wang, Li and Zhu, Yan and Liu, Lin and Xu, Shuang-Nian and Yang, Li and Pei, Cai-Xia and Zhan, Qian and Wang, Xin and Chen, Jian-Bin},
title = {A venetoclax‐cytarabine‐based induction regimen incorporating a translation inhibitor for adult patients with de novo acute myeloid leukemia},
journal = {Cancer},
year = {2026},
volume = {132},
number = {10},
doi = {10.1002/cncr.70432}
}
EUVIMED